Table 3.
Demographic and birth-related characteristics among commercially insured infants
| Birth-related characteristics | CLDP with Pali n = 586 |
CLDP w/o Pali n = 125 |
CHD with Pali n = 2525 |
CHD w/o Pali n = 6450 |
< 29 wGA with Pali n = 1223 |
< 29 wGA w/o Pali n = 382 |
29–30 wGA with Pali n = 1039 |
|---|---|---|---|---|---|---|---|
| Sex, n (%) | |||||||
| Male | 368 (62.8) | 81 (64.8) | 1341 (53.1) | 3239 (50.2) | 645 (52.7) | 203 (53.1) | 555 (53.4) |
| Female | 218 (37.2) | 44 (35.2) | 1184 (46.9) | 3211 (49.8) | 578 (47.3) | 179 (46.9) | 484 (46.6) |
| Birth hospitalization | |||||||
| Length of stay in days, median (range) | 66 (1–209) | 43 (1–192) | 23 (1–300) | 4 (1–212) | 74 (1–336) | 58 (1–207) | 45 (1–318) |
| Total cost in US$, median (range) | 273,539 (0–4,352,342) | 179,513 (0–1,946,891) | 134,282 (0–7,064,240) | 7014 (0–2,549,157) | 283,178 (0–5,078,734) | 185,733 (0–1,931,297) | 145,576 (0–2,197,190) |
| NICU admission, n (%) | 565 (96.4) | 112 (89.6) | 2130 (84.4) | 2562 (39.7) | 1189 (97.2) | 322 (84.3) | 1009 (97.1) |
| Presence of respiratory problems, n (%) | 558 (95.2) | 112 (89.6) | 1741 (69.0) | 1843 (28.6) | 1136 (92.9) | 290 (75.9) | 936 (90.1) |
| Age relative to the first RSV season, n (%) | |||||||
| Born during the RSV season | 260 (44.4) | 61 (48.8) | 1042 (41.3) | 2722 (42.2) | 527 (43.1) | 187 (49.0) | 382 (36.8) |
| < 3 months at start of RSV season | 141 (24.1) | 22 (17.6) | 684 (27.1) | 1311 (20.3) | 294 (24.0) | 76 (19.9) | 292 (28.1) |
| 3–6 months at start of RSV season | 139 (23.7) | 30 (24.0) | 622 (24.6) | 1719 (26.7) | 296 (24.2) | 84 (22.0) | 287 (27.6) |
| Birth-related characteristics | 29–30 wGA w/o Pali n = 581 | 31–32 wGA with Pali n = 1651 | 31-32 wGA w/o Pali n = 1773 | 33–34 wGA with Pali n = 1991 | 33–34 wGA w/o Pali n = 6642 | 35–36 wGA with Pali n = 574 | 35–36 wGA w/o Pali n = 17,620 |
|---|---|---|---|---|---|---|---|
| Sex, n (%) | |||||||
| Male | 328 (56.5) | 896 (54.3) | 949 (53.5) | 1061 (53.3) | 3701 (55.7) | 306 (53.3) | 9533 (54.1) |
| Female | 253 (43.5) | 755 (45.7) | 824 (46.5) | 930 (46.7) | 2941 (44.3) | 268 (46.7) | 8087 (45.9) |
| Birth hospitalization | |||||||
| Length of stay in days, median (range) | 42 (1–106) | 29 (1–122) | 25 (1–132) | 15 (1–130) | 13 (1–240) | 10 (1–141) | 4 (1–183) |
| Total cost in US$, median (range) | 132,856 (0–2,679,865) | 85,894 (0–2,179,730) | 67,693 (0–903,974) | 41,271 (0–633,084) | 33,037 (0–846,475) | 24,351 (0-713,298) | 6401 (0–1,126,573) |
| NICU admission, n (%) | 527 (90.7) | 1584 (95.9) | 1606 (90.6) | 1785 (89.7) | 5431 (81.8) | 438 (76.3) | 6840 (38.8) |
| Presence of respiratory problems, n (%) | 495 (85.2) | 1305 (79.0) | 1291 (72.8) | 1219 (61.2) | 3555 (53.5) | 312 (54.4) | 4635 (26.3) |
| Age relative to the first RSV season, n (%) | |||||||
| Born during the RSV season | 322 (55.4) | 674 (40.8) | 850 (47.9) | 877 (44.0) | 2794 (42.1) | 222 (38.7) | 7448 (42.3) |
| < 3 months at start of RSV season | 68 (11.7) | 490 (29.7) | 252 (14.2) | 690 (34.7) | 1132 (17.0) | 171 (29.8) | 3602 (20.4) |
| 3–6 months at start of RSV season | 98 (16.9) | 387 (23.4) | 409 (23.1) | 329 (16.5) | 1904 (28.7) | 157 (27.4) | 4795 (27.2) |
CHD congenital heart disease, CLDP chronic lung disease of prematurity, NICU neonatal intensive care unit, Pali palivizumab, RSV respiratory syncytial virus, SD standard deviation, wGA weeks gestational age